Intradermal injection
Intradermal injection | |
---|---|
MeSH | D007271 |
Intradermal injection (also intracutaneous or intradermic, abbreviated as ID) is a shallow or superficial
Vaccine dose sparing
For vaccination many clinical studies have proven efficacy of ID administration over subcutaneous (SC), intramuscular (IM) or other routes of administration. Since the COVID19 pandemic (2020) EMA and FDA promote the use of ID route of administration in case of possible vaccine shortage, for example during the Monkeypox outbreak in 2022 where 1/5th intradermal (fractional) dosing was advised, due to a risk of vaccine shortage.
Injection sites
Common injection sites include the inner surface of the forearm, the upper back, deltoid, thigh, and under the shoulder blade.[1] Injections sites are often chosen for skin thickness, preferring thicker skin.
Equipment
Equipment include
Mantoux procedure
The traditional procedure of ID injection known as the Mantoux procedure (as used in the
Intradermic needles
Traditionally hypodermic needles are used for intradermal injections, instead of intradermic needles. Various microneedle technology researchers worldwide develop new devices and therapies to overcome typical usability issues associated with the traditional Mantoux procedure. Most intradermic needles require a change in injection technique or instruction to use, for example a perpendicular intradermal injection.[4]
Immune reaction tests sometimes use a set of non-hollow needles for scarification, shallowly abrading the skin. The inoculation is limited to the dermis.
See also
- Subcutaneous injection
- Intramuscular injection
- Intravenous injection
References
- ^ ISBN 978-0-7817-9383-4.
- PMID 26037035.
- ^ "JYNNEOS Vaccine". Centers for Disease Control and Prevention. 2022-10-21. Retrieved 2022-10-23.
- PMID 23680534.